Myocardial infarction
Drug research and approvals for myocardial infarction: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 427 studies of myocardial infarction are recruiting on ClinicalTrials.gov, Health Canada has authorized 27 drug trials for it since 2013, and the EU has 20 authorised medicines for it.
- Recruiting worldwide: 427
- Trials authorized in Canada: 27
- FDA orphan approvals: 0
- EU medicines: 20
Recruiting Now
Newest start dates first, of 427 recruiting on ClinicalTrials.gov ↗- BRIDGE Trial: Embedding Consumer-grade mHealth Technologies Into Cardiac RehabilitationNCT07741396 · Not applicable · University of Illinois Chicago · starts Nov 2, 2026
- CRP Apheresis in Infarct-Related Cardiogenic ShockNCT07687017 · Not applicable · Leipzig Heart Science gGmbH · starts Oct 16, 2026
- INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for…NCT06965504 · Not applicable · Abiomed Inc. · starts Oct 2, 2026
- Enhancing Cardiac Rehabilitation Attendance After Secondary Myocardial Infarction Through Clinician Messaging and…NCT07485491 · Not applicable · Massachusetts General Hospital · starts Oct 1, 2026
- DAN-RELEASE - Reconsidering Long-Term Aspirin in the Elderly Patients With Stable Ischemic Heart DiseaseNCT07795398 · Phase 4 · Odense University Hospital · starts Sep 30, 2026
- Trends and Risk Factors of Adverse Cardiovascular and Cerebrovascular Events After Primary PCINCT07833995 · Not reported · Shanghai Zhongshan Hospital · starts Sep 28, 2026
- A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular DiseaseNCT07839936 · Phase 2 · Verve Therapeutics, Inc. · starts Sep 24, 2026
- ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic…NCT07545512 · Not applicable · University Hospital, Clermont-Ferrand · starts Sep 24, 2026
- NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic StrokeNCT07828210 · Phase 4 · EVD Pharmacy and Medical Company Limited · starts Sep 10, 2026
- Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic ShockNCT07583446 · Phase 2 / Phase 3 · Seismic Pharmaceuticals Operations LLC · starts Sep 9, 2026
Trials Authorized in Canada
The 10 newest of 27; search them all in Canada trials| Nov 5, 2025 | Evaluation of an aspirin-free strategy with ticagrelor in patients with a myocardial infarction treated medically alone (pantheon) [placebo controlled]TICAGRELOR / ACETYLSALICYLIC ACID | MONTREAL HEART INSTITUTE | Ongoing |
| Feb 20, 2024 | Artemis - effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction.ZILTIVEKIMAB | Novo Nordisk | Ongoing |
| Aug 22, 2023 | Randomized, double-blind, placebo-controlled study to investigate a single administration of bi 765845 on top of standard of care in patients with acute…BI 765845 | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Ongoing |
| Jun 22, 2022 | A phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study to assess the safety and efficacy of a single subcutaneous…ZALUNFIBAN | CELECOR THERAPEUTICS, INC. | Closed |
| Dec 16, 2021 | Iocyte ami-3: a phase 3, randomized, double-blind, placebo-controlled, multicenter study of intravenous fdy-5301 in patients with an anterior st-elevation…FDY-5301 | FARADAY PHARMACEUTICALS, INC. | Closed |
| Aug 18, 2021 | Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous…SELATOGREL (ACT-246475) | Viatris | Ongoing |
| Dec 16, 2020 | Empact-mi: a streamlined, multicentre, randomised, parallel group, doubleblind placebo-controlled superiority trial to evaluate the effect of empagliflozin on…EMPAGLIFLOZIN | Boehringer Ingelheim Pharmaceuticals, Inc. | Closed |
| Nov 27, 2020 | Rivaroxaban in type 2 myocardial infarctions: a feasibility, placebo-controlled, double-blinded, randomized controlled trialRIVAROXABAN | GOVERNORS OF THE UNIVERSITY OF ALBERTA | Closed |
| Sep 9, 2020 | A phase IIb, randomized, double-blinded, placebo-controlled, parallel-group study to evaluate the efficacy and safety of medi6570 in participants with a prior…MEDI6570 | AstraZeneca Pharmaceuticals LP | Ongoing |
| Aug 12, 2020 | Sonothrombolysis in patients with an st-segment elevation myocardial infarction with fibrinolysis (sonostemi-lysis) trialPERFLUTREN | GOVERNORS OF THE UNIVERSITY OF ALBERTA | Closed |
Medicines Authorised in the EU
Newest first; 15 of 20| Jul 24, 2026 | Colchicine Agepha Pharmacolchicine | Agepha Pharma s.r.o. | EMA ↗ |
| May 15, 2018 | Prasugrel Viatris (previously Prasugrel Mylan)prasugrel · generic | Viatris Limited | EMA ↗ |
| Jan 11, 2016 | Eptifibatide Accordeptifibatide · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Feb 18, 2015 | Clopidogrel ratiopharmclopidogrel · generic | Teva B.V. | EMA ↗ |
| Dec 3, 2010 | Briliqueticagrelor | AstraZeneca AB | EMA ↗ |
| Oct 28, 2010 | Clopidogrel HCSclopidogrel · generic | HCS bvba | EMA ↗ |
| Mar 14, 2010 | Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover)clopidogrel;acetylsalicylic acid | Sanofi-Aventis Groupe | EMA ↗ |
| Oct 16, 2009 | Clopidogrel Viatris (previously Clopidogrel Taw Pharma)clopidogrel · generic | Viatris Limited | EMA ↗ |
| Sep 28, 2009 | Zylltclopidogrel · generic | KRKA tovarna zdravil d.d. Novo mesto | EMA ↗ |
| Sep 23, 2009 | Clopidogrel Krkaclopidogrel · generic | KRKA tovarna zdravil d.d. Novo mesto | EMA ↗ |
| Sep 23, 2009 | Clopidogrel TADclopidogrel · generic | Tad Pharma GmbH | EMA ↗ |
| Sep 21, 2009 | Clopidogrel Taw Pharma (previously Clopidogrel Mylan)clopidogrel · generic | Taw Pharma (Ireland) Limited | EMA ↗ |
| Sep 21, 2009 | Clopidogrel BGR (previously Zylagren)clopidogrel · generic | Biogaran | EMA ↗ |
| Sep 20, 2009 | Clopidogrel Krka d.d. (previously Zopya)clopidogrel · generic | Norpharm Regulatory Services Ltd | EMA ↗ |
| Jul 27, 2009 | Grepidclopidogrel · generic | Pharmathen S.A. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA